Imexpharm Corp (VN:IMP) — Market Cap & Net Worth
Market Cap & Net Worth: Imexpharm Corp (IMP)
Imexpharm Corp (VN:IMP) has a market capitalization of $269.75 Million (₫7.10 Trillion) as of June 17, 2026. Listed on the VN stock exchange, this Vietnam-based company holds position #15454 globally and #85 in its home market, demonstrating a 0.66% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Imexpharm Corp's stock price ₫46100.00 by its total outstanding shares 154008962 (154.01 Million). Review IMP total debt and obligations to assess the company's total debt and financial obligations.
Imexpharm Corp Market Cap History: 2015 to 2026
Imexpharm Corp's market capitalization history from 2015 to 2026. Data shows growth from $43.64 Million to $269.75 Million (17.64% CAGR).
Imexpharm Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Imexpharm Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Imexpharm Corp's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.00x
Imexpharm Corp's market cap is 0.00 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $82.49 Million | $1.40 Trillion | $162.39 Billion | 0.00x | 0.00x |
| 2020 | $128.60 Million | $1.37 Trillion | $209.70 Billion | 0.00x | 0.00x |
| 2021 | $181.11 Million | $1.27 Trillion | $189.09 Billion | 0.00x | 0.00x |
| 2022 | $143.34 Million | $1.64 Trillion | $223.54 Billion | 0.00x | 0.00x |
| 2023 | $148.51 Million | $1.99 Trillion | $299.56 Billion | 0.00x | 0.00x |
| 2024 | $275.02 Million | $2.21 Trillion | $320.86 Billion | 0.00x | 0.00x |
| 2025 | $307.20 Million | $2.44 Trillion | $349.14 Billion | 0.00x | 0.00x |
Competitor Companies of IMP by Market Capitalization
Companies near Imexpharm Corp in the global market cap rankings as of June 17, 2026.
Key companies related to Imexpharm Corp by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #513 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #561 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #624 globally with a market cap of $44.20 Billion USD ( CN¥302.05 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #513 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #561 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.22 |
| #624 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.20 Billion | CN¥47.35 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
Imexpharm Corp Historical Marketcap From 2015 to 2026
Between 2015 and today, Imexpharm Corp's market cap moved from $43.64 Million to $ 269.75 Million, with a yearly change of 17.64%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₫269.75 Million | -12.19% |
| 2025 | ₫307.20 Million | +11.70% |
| 2024 | ₫275.02 Million | +85.18% |
| 2023 | ₫148.51 Million | +3.61% |
| 2022 | ₫143.34 Million | -20.86% |
| 2021 | ₫181.11 Million | +40.83% |
| 2020 | ₫128.60 Million | +55.90% |
| 2019 | ₫82.49 Million | -17.90% |
| 2018 | ₫100.47 Million | +6.11% |
| 2017 | ₫94.68 Million | +32.75% |
| 2016 | ₫71.33 Million | +63.45% |
| 2015 | ₫43.64 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Imexpharm Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $269.75 Million USD |
| MoneyControl | $269.75 Million USD |
| MarketWatch | $269.75 Million USD |
| marketcap.company | $269.75 Million USD |
| Reuters | $269.75 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Imexpharm Corp
Imexpharm Corporation operates as a pharmaceutical company in Vietnam. The company's products include injectable antibiotics, oral antibiotics, cardiovascular, ophthalmology, musculoskeletal system, analgesic - anti-inflammatory - antipyretics, respiratory system, antihistamines and anti-allergy, central nervous system, digestive system, diabetes, anti-parasitic, external drugs, vitamins and mine… Read more